Table 1.
Characteristics of adverse event reports for drospirenone-containing oral contraceptives and second/third generation oral contraceptives
| Drospirenone-containing oral contraceptives | Second/third generation oral contraceptives | P value | |
| N (%) | N (%) | ||
| Total | 2013 (100) | 4350 (100) | – |
| Age (years) | <0.0001* | ||
| 1–19 | 57 (2.83) | 50 (1.15) | |
| 20–29 | 375 (18.63) | 517 (11.89) | |
| 30–39 | 281 (13.96) | 185 (4.25) | |
| ≥40 | 219 (10.88) | 99 (2.28) | |
| Unknown | 1081 (53.70) | 3499 (80.44) | |
| Period of use (months) | <0.0001* | ||
| 0–1 | 242 (12.02) | 300 (6.90) | |
| 1–3 | 118 (5.86) | 40 (0.92) | |
| 3–5 | 37 (1.84) | 14 (0.32) | |
| >5 | 87 (4.32) | 32 (0.74) | |
| Unknown | 1529 (75.96) | 3964 (91.13) | |
| Serious adverse events | 0.2333 | ||
| Total | 158 (7.85) | 127 (2.92) | |
| Death | 5 (0.25) | 1 (0.02) | |
| Reporting group by profession | <0.0001* | ||
| Doctors | 252 (12.52) | 18 (0.41) | |
| Pharmacists | 364 (18.08) | 362 (8.32) | |
| Nurses | 101 (5.02) | 19 (0.44) | |
| Consumers | 925 (45.95) | 2844 (65.38) | |
| Others | 199 (9.89) | 638 (14.67) | |
| Unknown | 172 (8.54) | 469 (10.78) | |
*P value of <0.05: significant.